TeamDrive
RUS

RUSNANO

http://en.rusnano.com/

RUSNANO was founded as a joint stock company in March 2011, through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO is instrumental in realizing government policies for nanoindustry growth, investing in financially effective high-technology projects that guarantee the development of new manufacturing within the Russian Federation. The company invests in nanotechnology companies directly and through investment funds. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. By the moment thanks to RUSNANO’s investments 73 plants and R&D centers are launched in 32 regions of Russia.

Management of the investment assets of RUSNANO are carried out by a limited liability company established in December 2013, RUSNANO Asset Management. Anatoly Chubais is Chairman of its Executive Board.

Media Center

  • 17 August 2018

    Researchers developed a new class of drugs to reduce cardiovascular risk

    Researchers from Cleveland Clinic (Cleveland, Ohio, USA) have designed a potential new class of drugs that may reduce cardiovascular risk by targeting a specific microbial pathway in the gut.

  • 16 August 2018

    The Pulse of Biopharma M&A

    M&A-driven dealmaking in 2018 across the biopharmaceutical industry is on track to becoming the second highest of the decade. “There’s been a significant increase in private financing, principally driven by Series A financing, which tells us that new company formation has accelerated in the last four to five years,” says Neel Patel, managing director, commercial strategy and planning, at Syneos Health Consulting, and co-author of theNeel Patel 2018 Dealmakers’ Intention Study. 

  • 15 August 2018

    What Issues Are Top of Mind for Smaller Biotech and Emerging Biopharma Companies?

    As a small biotech company proceeds from startup phase through rapid growth of its operations, it will face many critical decisions along the way. Indeed, many of the decisions will be pivotal to determining whether the company will successfully move from a small incubator of ideas to the ability to shepherd a R&D asset through its pipeline to achieving commercial success. This article will provide readers with selected examples of such decisions, plus questions or factors to be considered when making decisions that will have significant impact on the future of their growing firm. 

  • 14 August 2018

    FPI conducts preclinical trials of drug intended to save seriously injured

    Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).

Read more